Track topics on Twitter Track topics that are important to you
In the first of two acquisitions announced on the same day, both focused on the emerging non-alcoholic steatohepatitis (NASH) market, Allergan PLC bought publicly traded Tobira Therapeutics Inc. for $1.695bn, including approximately $534mm up front plus up to $1.2bn in earn-outs.
Original Article: Allergan acquires NASH player Tobira for $1.695bnNEXT ARTICLE
Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.